Compare ARK Fintech Innovation ETF (ARKF) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Citius Pharmaceuticals Inc — how do they compare? ARK Fintech Innovation ETF trades at $43, while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: ARK Fintech Innovation ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKF | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $1.82 |
52-Week Low | $36.14 | $0.48 |
Market Cap | — | $18.73M |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.54, up 1.48% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has underperformed the S&P 500, down 23% since July 2025, and faces elevated volatility. Recent news highlights its fintech and crypto exposure amid market consolidation, with a Hold rating due to fair valuation concerns.
Outlook remains cautious; high P/E of 33x and PEG of 2.0x suggest overvaluation risks, while sector consolidation offers potential recovery if market sentiment improves. Key risks include sustained underperformance and portfolio volatility, requiring careful monitoring of fintech sector trends.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
